BioImagene, the leading provider of innovative digital pathology solutions, today announced the availability of the next generation of its digital pathology solution, VirtuosoTM. A highlight in this version is the ability to share cases in real time, allowing pathologists to collaborate with each other to sign out cases. Virtuoso users can participate in peer reviews, perform second-opinions for difficult cases, and guide residents in the review of cases for education.
Virtuoso will be demonstrated at the BioImagene Booth 411 at the CAP ‘09 – THE Pathologists Meeting™ that will be held in Washington, D.C. from October 11 – 14, 2009.
Stephen G. Ruby, MD, MBA, FCAP, president and medical director, 4path, Ltd. noted, “I had determined that a digital image platform would be an integral part of the development of 4path's new state of the art out-patient focused anatomic pathology laboratory. With nearly 20 years of imaging experience, it was clear to me that there was significant maturity to current image solutions and that image analysis is becoming an essential tool to pathologists. 4path selected Virtuoso as its platform for our digital imaging initiatives, allowing us to incorporate both the quantitative image analysis algorithms and the remote consultative capabilities into our practice. BioImagene is an essential component in providing both anatomic diagnostic and interactive consultative services to our clients and their patients."
The new Virtuoso release includes many new algorithms, further enabling personalized medicine. BioImagene now offers more than 100 algorithms which include IHC algorithms such as HER2, ER/PR and p53 for breast cancer, Ki67 for breast, brain and prostate cancers, CD138 for multiple myeloma and CD3/CD20 for lymphoma. These specialized algorithms aid pathologists in the quantitative assessment of biomarkers that in many cases help determine patient suitability for specific cancer therapies.
“We are excited to roll out the latest digital pathology tools to help pathologists offer quantitative diagnostic insights that are critical when taking a personalized medicine approach to treatment,” said Dr. Ajit Singh, chief executive officer of BioImagene. “We have made it easy for pathologists and laboratories to acquire our systems as we are the only company to offer comprehensive pay-per-click pricing model. There is no upfront expense, as we provide the software and equipment, and the lab only pays every time they scan a slide or analyze it.”
Virtuoso now includes:
- Real-time collaboration
- Powerful analysis algorithms for breast, prostate, and other panels of IHC markers
- Enhanced reporting, which allows pathologists to provide oncologists with detailed information to make better treatment decisions
- Improved and more intuitive user interface
Virtuoso works with BioImagene's iScanTM family of slide scanners to provide an end-to-end workflow solution. It allows users to view, manage, manipulate and analyze digital images, produce digital reports and collaborate with one another.
International team releases recommendations for AI use in neuro-oncology